Nextcure announces presentations on targets in development by collaborators at american society of hematology annual meeting

Beltsville, md., nov. 04, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two research studies will be presented during oral and poster sessions at the 63rd annual american society of hematology (ash) annual meeting, to be held in atlanta, georgia and in a virtual platform on december 11-14, 2021.
NXTC Ratings Summary
NXTC Quant Ranking